Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4285-4292

  Czuczman, Myron S ^a   Emmanouilides, Christos ^a   Darif, Mohamed ^a   Witzig, Thomas E ^a   Gordon, Leo I ^a   Revell, Stephen ^a   Vo, Katie ^a   Molina, Arturo ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; YTTRIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 34948845600     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.2882     Document Type: Article

References (42)

1. Armitage JO, Carbone PP, Connors JM, et al: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 21:897-906, 2003
2. Astrow AB: Fludarabine-related myeloid leukemia. J Clin Oncol 21:3709, 2003
3. Leone G, Mele L, Pulsoni A, et al: The incidence of secondary leukemias. Haematologica 84:937-945, 1999
4. Thirman MJ, Larson RA: Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 10:293-320, 1996
5. Scheinberg DA, Maslak P, Weiss M: Myelodysplastic syndromes, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 2388-2396
6. Smith SM, Le Beau MM, Huo D, et al: Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102:43-52, 2003
7. Kern W, Haferlach T, Schnittger S, et al: Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 22:2510-2511, 2004
8. Mauritzson N, Albin M, Rylander L, et al: Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 16:2366-2378, 2002
9. McLaughlin P, Estey E, Glassman A, et al: Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105:4573-4575, 2005
10. Morrison VA, Rai KR, Peterson BL, et al: Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: Results of an Intergroup study. Cancer and Leukemia Group B 9011. J Clin Oncol 20:3878-3884, 2002
11. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103:195-200, 1985
12. Misgeld E, Germing U, Aul C, et al: Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. Leuk Res 25:95-98, 2001
13. Kantarjian HM, Keating MJ: Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 14:435-443, 1987
14. Orchard JA, Bolam S, Oscier DG: Association of myelodysplastic changes with purine analogues. Br J Haematol 100:677-679, 1998
15. Coso D, Costello R, Cohen-Valensi R, et al: Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. Ann Oncol 10:362-363, 1999
16. Gomez GA, Aggarwal KK, Han T: Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma. Cancer 50:2285-2288, 1982
17. Greene MH, Young RC, Merrill JM, et al: Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 43:1891-1898, 1983
18. Ingram L, Mott MG, Mann JR, et al: Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens. Br J Cancer 55:463-466, 1987
19. Lavey RS, Eby NL, Prosnitz LR: Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 66:80-88, 1990
20. Travis LB, Weeks J, Curtis RE, et al: Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 14:565-571, 1996
21. Mendenhall NP, Noyes WD, Million RR: Total body irradiation for stage M-IV non-Hodgkin's lymphoma: Ten-year follow-up. J Clin Oncol 7:67-74, 1989
22. Andre M, Mounier N, Leleu X, et al: Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood 103:1222-1228, 2004
23. Zevalin (ibritumomab tiuxetan) prescribing information. Cambridge, MA, Biogen Idec, 2005
24. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003
25. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
26. Witzig TE, Rinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
27. Wiseman GA, Gordon LI, Multani PS, et al: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 99:4336-4342, 2002
28. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
29. Gordon LI, Molina A, Witzig T, et al: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004
30. Witzig TE, Molina A, Gordon LI, et al: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin's lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109:1804-1810, 2007
31. Breslow NE, Day NE: Statistical Methods in Cancer Res, Vol 2: The Design and Analysis of Cohort Studies (IARC publication no. 82). Lyon, France, International Agency for Research on Cancer, 1987
32. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representation of old estimators. Stat Med 18:695-706, 1999
33. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
34. Bennett JM, Kaminski MS, Leonard JP, et al: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 1131 tositumomab. Blood 105:4576-4582, 2005
35. Vose JM, Chiu BC, Cheson BD, et al: Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 241-262, 2002
36. Emmanouilides C, Witzig TE, Gordon LI, et al: Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 47:629-636, 2006
37. 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Res Network phase II trial. J Clin Oncol 23:579s, 2005 (suppl; abstr 6577)
38. 90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood 104:720a, 2004 (abstr 2633)
39. 90Y) ibritumomab tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 106:689a-690a, 2005 (abstr 2452)
40. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005
41. Cheson BD, Vena DA, Barrett J, et al: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17:2454-2460, 1999
42. Nabhan C, Peterson LA, Kent SA, et al: Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma. Leuk Lymphoma 43:2145-2149, 2002